The first China-originated CDK4/6 inhibitor, Hengrui Medicine Dalsili, was launched nationwide

On February 26, 2022, the launch meeting of the first Chinese original CDK4/6 inhibitor Dalcil (Ericang®) independently developed by Hengrui Medicine was held in 13 cities across the country, with the main venues in Shanghai, Beijing and Guangzhou.

Academician Xu Binghe of Cancer Hospital of Chinese Academy of Medical Sciences, Professor Jiang Zefei of PLA General Hospital, Professor Yin Yongmei of Jiangsu Provincial People's Hospital, Professor Wang Xiaojia of Cancer Hospital Affiliated to University of Chinese Academy of Sciences, Professor Liu Qiang of Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Professor Wang Shusen of Sun Yat-sen University Cancer Center, Chinese Medicine Professor Ma Fei from the Cancer Hospital of the Chinese Academy of Sciences, Professor Zhang Pin from the Cancer Hospital of the Chinese Academy of Medical Sciences, Professor Yu Keda from the Fudan University Cancer Hospital, Professor Li Qiao from the Cancer Hospital of the Chinese Academy of Medical Sciences, Professor Chen Qianjun from the Guangdong Provincial Hospital of Traditional Chinese Medicine and other experts Attend at the main venue

Professor Zhang Qingyuan of the Cancer Hospital Affiliated to Harbin Medical University, Professor Geng Cuizhi of the Fourth Hospital of Hebei Medical University, Professor Feng Jifeng of the Jiangsu Cancer Hospital, Professor Jin Feng of the First Affiliated Hospital of China Medical University, Professor Teng Yuee of the First Affiliated Hospital of China Medical University, Tianjin Medical University Oncology Professor Tong Zhongsheng from the hospital, Professor Liu Zhenzhen from Henan Cancer Hospital, Professor Ouyang Quchang from Hunan Cancer Hospital, Professor Chen Gannong from the Second Xiangya Hospital of Central South University, Professor Ling Rui from Xijing Hospital of Air Force Military Medical University, Professor Wang Haibo from Qingdao University Affiliated Hospital and Luo from West China Hospital of Sichuan University Professor Ting and other experts attended the sub-venue

This listing will follow the logic line of "Greeding-Sprouting-Birth-Growing-Accompanying" of Dalsili, and describes the process of project establishment, R&D and launch of CDK4/6 inhibitor Dalsili

Ten years of sharpening a sword, focusing on patient needs to promote research and development

At the beginning of the meeting, through the short play of the dawn of dawn, the R&D team led by Zhang Lianshan, deputy general manager of Hengrui Medicine, reviewed the original intention of Dalcil

Prof.

Review the road of exploration and share the journey of the heart

The road to R&D and market launch of Dalsili in China

The conference also retraced Dalsili's eight-year exploration journey from 2013 to 2021

100% Chinese evidence-based, closer to Chinese patients

Dalsili's Phase III clinical registration study (DAWNA-1 study) will be listed in the top international journal Nature Medicine (Impact Factor: 53.

Academician Xu Binghe pointed out that 100% of the patients enrolled in the DAWNA-1 study were Chinese, 27% of the patients in the Dalcieri study group had received chemotherapy in the past rescue treatment, and 44% of the premenopausal (perimenopausal) patients were close to Chinese breast cancer.

Subsequently, Professor Ma Fei of Cancer Hospital of Chinese Academy of Medical Sciences, Professor Hu Xichun of Cancer Hospital Affiliated to Fudan University, Professor Wang Xiaojia of Cancer Hospital Affiliated to University of Chinese Academy of Sciences, Professor Zhang Pin of Cancer Hospital of Chinese Academy of Medical Sciences and Professor Jin Feng of the First Affiliated Hospital of China Medical University, Prof.

Set sail and strive to benefit more patients

At the meeting, Professor Jiang Zefei from PLA General Hospital, Professor Yin Yongmei from Jiangsu Provincial People's Hospital, Professor Wu Jiong from Fudan University Cancer Hospital, Professor Shao Zhimin from Fudan University Cancer Hospital, Professor Zhang Qingyuan from Harbin Medical University Cancer Hospital, Professor Liu Qiang from Sun Yat-sen Memorial Hospital of Sun Yat-Sen University, Professor Geng Cuizhi from the Fourth Hospital of Hebei Medical University jointly discussed medical practice, clinical research, and the future development of Chinese companies going international

The national listing meeting of Dalsili reached a climax in the exciting listing ceremony.

Academician Xu Binghe of the Cancer Hospital of the Chinese Academy of Medical Sciences concluded that Dalsili is currently the fourth CDK4/6 inhibitor to be marketed in the world